title: 109881 Aventis.
abstract: 109881 is an orally and intravenously active taxoid in development by Aventis Pharma (formerly Rhône-Poulenc Rorer) as a potential treatment for a variety of taxoid-resistant solid tumors, such as brain and lung cancers. As of April 2000, the compound was in phase IIa trials in the US, France, Belgium and Germany. Phase II trials were ongoing in May 2001, and the company was evaluating an oral formulation at this time.
authors.affiliation: Department of Chemistry, Institute of Chemical Biology and Drug Discovery, State University of New York at Stony Brook, Stony Brook, NY 11794-3400, USA. iojima@notes.cc.sunysb.edu
authors.forename: Iwao
authors.initials: I
authors.lastname: Ojima
authors.forename: Raphaël
authors.initials: R
authors.lastname: Geney
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000737:chemistry / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D015507:Drugs, Investigational / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D013678:Technology, Pharmaceutical / Q000379:methods*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D015507:Drugs, Investigational